Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Hepatology (Baltimore, Md.) - 1 Nov 2014

Carlsen Thomas H R, Pedersen Jannie, Prentoe Jannick C, Giang Erick, Keck Zhen-Yong, Mikkelsen Lotte S, Law Mansun, Foung Steven K H, Bukh Jens

Abstract excerpt

UNLABELLED: Human monoclonal antibodies (HMAbs) with neutralizing capabilities constitute potential immune-based treatments or prophylaxis against hepatitis C virus (HCV). However, lack of cell culture-derived HCV (HCVcc) harboring authentic envelope proteins (E1/E2) has hindered neutralization investigations across genotypes, subtypes, and isolates. We investigated the breadth of neutralization of 10 HMAbs with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C virus research

Share to Neutralization Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 25043937
DOI: 10.1002/hep.27298
PMCID: PMC4415877

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.PMID 25043937Read ↗

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization ResistanceSemantic proximity Read ↗

Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.Semantic proximity Read ↗

Defining Breadth of Hepatitis C Virus Neutralization.Semantic proximity Read ↗

Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Semantic proximity Read ↗

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.Semantic proximity Read ↗

Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinSemantic proximity Read ↗

Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C VirusSemantic proximity Read ↗

Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.Semantic proximity Read ↗

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal AntibodiesSemantic proximity Read ↗

Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesSemantic proximity Read ↗

Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment StepSemantic proximity Read ↗

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.